Edesa Biotech CEO Buys 1,159 Shares in Insider Surge, Eyes Upcoming FDA Milestones
CEO Pardeep Nijhawan’s fresh buy of 1,159 Edesa Biotech shares signals deep insider confidence in its dermatology pipeline and upcoming milestones.
3 minutes to read
Edesa Biotech Inc
Edesa Biotech CEO Buys 600,000+ Shares Amid Clinical Milestone Hopes, Stock Remains Deeply Discounted
CEO’s fresh insider buy of Edesa Biotech shares shows confidence in upcoming clinical milestones, hinting at a potential upside for long‑term investors.
3 minutes to read
Edesa Biotech CEO’s Steady Share‑Buying Signals Bold Confidence as Stock Soars 516% YoY
CEO Pardeep Nijhawan’s steady buying at low prices shows Edesa Biotech’s strong outlook—boosted by 516% monthly earnings, 58% weekly gains and a disciplined 10k‑share strategy. Investors may spot upside before the stock hits new highs.
3 minutes to read
Edesa Biotech CEO Pardeep Rakes Up 10,000 Shares in Bold Buy‑Frenzy, Betting on Future Pipeline Amid Negative P/E and Volatile Stock Price
CEO’s recent 10,000‑share buy at $3.26 signals confidence for Edesa Biotech, yet investors must weigh weak earnings, clinical milestones, and potential dilution.
3 minutes to read
Edesa Biotech CEO Buys 10,000 Shares Amid Rising Social‑Media Buzz and Insider Confidence
Insider buying boosts optimism for Edesa Biotech—CEO’s latest 10k-share purchase signals confidence ahead of key clinical milestones.
3 minutes to read
Edesa Biotech CEO Buys $2 Shares Amid 337% Rally, Bolstering Investor Optimism
CEO Nijhawan Pardeep’s recent bulk buy of Edesa Biotech shares at $2 each signals bullish confidence amid a 337% rally, suggesting optimism for upcoming clinical milestones.
2 minutes to read
Edesa Biotech CEO Buys Shares at Discount, Signals Confidence in Upcoming Pipeline Milestones
CEO Nijhawan Pardeep’s recent bulk buying of Edesa Biotech shares signals insider confidence, hinting at potential upside as the company advances its clinical pipeline.
3 minutes to read